Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
Portfolio Pulse from Vandana Singh
Tarsus Pharmaceuticals' Xdemvy has been approved by the FDA for Demodex blepharitis. Despite this, Tarsus shares have been under pressure due to concerns over a 10% instillation site stinging and burning adverse event. Analysts from William Blair believe these concerns are overblown and maintain an Outperform rating with a price target of $44. They also note that the weakness in Tarsus shares may be due to cases of eye inflammation and occlusive retinal vasculitis for Apellis Pharmaceuticals' Syfovre.

July 25, 2023 | 7:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals' Syfovre may be causing weakness in Tarsus shares due to cases of eye inflammation and occlusive retinal vasculitis.
Analysts believe that the cases of eye inflammation and occlusive retinal vasculitis for Apellis' Syfovre may be causing weakness in Tarsus shares. This indicates a potential indirect impact on Apellis.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Tarsus shares are under pressure despite FDA approval for Xdemvy. Analysts maintain an Outperform rating and believe concerns over adverse events are overblown.
The FDA approval for Xdemvy should have been a positive catalyst for Tarsus shares. However, concerns over adverse events have put pressure on the stock. Analysts believe these concerns are overblown and maintain an Outperform rating, indicating potential upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100